The role of tumor stroma in the interaction between tumor and immune system

Current Opinion in Immunology

Volumn 17, Issue 2, 2005, Pages 180-186

  Blankenstein, Thomas ^a,b  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD8 ANTIGEN; CYTOKINE; FAS LIGAND; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; PERFORIN;

ANGIOGENESIS; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; BONE MARROW CELL; CELL ACTIVITY; CELL DEATH; CELL TYPE; CYTOTOXIC T LYMPHOCYTE; ENDOTHELIUM CELL; FIBROBLAST; IMMUNE SYSTEM; LYSIS; MACROPHAGE; MOLECULE; PARACRINE SIGNALING; REVIEW; SOLID TUMOR; STROMA; STROMA CELL; T LYMPHOCYTE; TUMOR CELL; TUMOR REJECTION;

EID: 14844297325     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2005.01.008     Document Type: Review

References (57)

1. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70
2. H. Schreiber, and D.A. Rowley Inflammation and cancer J.I. Edited by Gallin R. Snyderman Inflammation: Basic Principles and Clinical Correlates 1999 Lippincott Williams and Wilkins 1117 1129
3. T.D. Tlsty, and P.W. Hein Know thy neighbor: stromal cells can contribute oncogenic signals Curr Opin Genet Dev 11 2001 54 59
4. B. Elenbaas, and R.A. Weinberg Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation Exp Cell Res 264 2001 169 184
5. M. Bissel, and D. Radisky Putting tumours in context Nat Rev Cancer 1 2001 46 54
6. B. Wiseman, and Z. Werb Stromal effects on mammary gland development and breast cancer Science 296 2002 1046 1049
7. N.A. Bhowmick, A. Chytil, D. Plieth, A.E. Gorska, N. Dumont, S. Shappell, M.K. Washington, E.G. Neilson, and H.L. Moses TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia Science 303 2004 848 851 By conditional Cre/Lox KO technology, this study shows that mice whose fibroblasts cannot respond to TGF-β develop epithelial carcinomas.
8. R.J. Barth Jr., J.J. Mule, P.J. Spiess, and S.A. Rosenberg Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes J Exp Med 173 1991 647 658
9. C. Becker, H. Pohla, B. Frankenberger, T. Schuler, M. Assenmacher, D.J. Schendel, and T. Blankenstein Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay Nat Med 7 2001 1159 1162
10. T. Blankenstein, and Z. Qin The role of IFNγ in tumor transplantation immunity and inhibition of chemical carcinogenesis Curr Opin Immunol 15 2003 148 154 This review summarizes data showing that IFN-γ contributes to the rejection of transplanted tumors and to the inhibition of methylcholanthrene-induced fibrosarcomas by different mechanisms.
11. B. Stoelker, B. Ruhland, T. Hehlgans, H. Bluethmann, T. Luther, and D.N. Männel Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature Am J Pathol 156 2000 1171 1176
12. M.F. Van den Broek, D. Kägi, F. Ossendorp, R. Toes, S. Vamvakas, W.K. Lutz, Melief CJM, R.M. Zinkernagel, and H. Hengartner Decreased tumor surveillance in perforin-deficient mice J Exp Med 184 1996 1781 1790
13. H. Winter, H.M. Hu, W.J. Urba, and B.A. Fox Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L) J Immunol 163 1999 4462 4472
14. H. Winter, H.M. Hu, K. McClain, W.J. Urba, and B.A. Fox Immunotherapy of melanoma: a dichotomy in the requirement for IFN-γ in vaccine-induced antitumor immunity versus adoptive immunotherapy J Immunol 166 2001 7370 7380
15. + T cell mediated tumor immunity involves inhibition of angiogenesis which is dependent on IFNγ receptor expression by non-hematopoietic cells Immunity 12 2000 677 686
16. A. Prevost-Blondel, M. Neuenhahn, M. Rawiel, and H. Pircher Differential requirement of perforin and IFN-gamma in CD8 T cell-mediated immune responses against B16.F10 melanoma cells expressing a viral antigen Eur J Immunol 30 2000 2507 2515
17. L. Peng, J.C. Krauss, G.E. Plautz, S. Mukai, S. Shu, and P.A. Cohen T cell-mediated tumor rejection displays diverse dependence upon perforin and IFN-gamma mechanisms that cannot be predicted from in vitro T cell characteristics J Immunol 165 2000 7116 7124
18. S. Ibe, Z. Qin, T. Schüler, S. Preiss, and Th. Blankenstein Tumor rejection by disturbing tumor stroma cell interactions J Exp Med 194 2001 1549 1560
19. J.M. Wigginton, E. Gruys, L. Geiselhart, J. Subleski, K.L. Komschlies, J.W. Park, T.A. Wiltrout, K. Nagashima, T.C. Back, and R.H. Wiltrout IFN-γ and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy J Clin Invest 108 2001 51 62
20. A. van Elsas, Sutmuller RPM, A.A. Hurwitz, J. Ziskin, J. Villasenor, J.P. Medema, W.W. Overwijk, N.P. Restifo, C.J.M. Melief, R. Offringa, and J.P. Allison Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy J Exp Med 194 2001 481 489
21. N. Seki, A.D. Brooks, C.R. Carter, T.C. Back, E.M. Parsoneault, M.J. Smyth, R.H. Wiltrout, and T.J. Sayers Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin J Immunol 168 2002 3484 3492
22. •].
23. + effector T cells 'see' antigen on the tumor cells and produce IFN-γ, which acts on the host, probably on tumor stromal cells.
24. C.H. Poehlein, H.M. Hu, J. Yamada, I. Assmann, W.G. Alvord, W.J. Urba, and B.A. Fox TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells J Immunol 170 2003 2004 2013 T cells which are doubly deficient in perforin and IFN-γ are unable to reject tumors in adoptive T cell transfer models. If large numbers of T cells are transferred, the immune deficiency is obviated.
25. •].
26. + effector T cells. Tumor rejection requires large amounts of tumor-derived antigen.
27. + effector T cells involves IFN-γ-mediated inhibition of tumor-induced angiogenesis.
28. P. Nanni, L. Landuzzi, G. Nicoletti, C. De Giovanni, I. Rossi, S. Croci, A. Astolfi, M. Iezzi, E. Di Carlo, and P. Musiani Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-γ and B cell dependent J Immunol 173 2004 2288 2296 Successful vaccination of cancer-prone Her2 transgenic mice requires IFN-γ and involves antiangiogenesis. The source of IFN-γ is not yet clear.
29. J.A. Hollenbough, J. Reome, M. Dobrzanski, and R.W. Dutton The rate of the CD8- dependent initial reduction in tumor volume is not limited by contact-dependent perforin, Fas ligand, or TNF-mediated cytolysis J Immunol 173 2004 1738 1743 Adoptively transferred CD8+ effector T cells with multiple cytolytic defects can reject tumors but IFN-γ is required.
30. T.H. Wu, C.N. Pabin, Z. Qin, Th. Blankenstein, M. Philip, J. Dignam, K. Schreiber, and H. Schreiber Long-term suppression of tumor growth by TNF requires a Stat1- and IFN response factor 1-dependent IFNγ pathway but not IL-12 or IL-18 J Immunol 172 2004 3243 3251 Rejection of TNF-α-secreting tumors requires TNF receptor expression on non-bone-marrow-derived tumor stromal cells, probably to inhibit angiogenesis. Surprisingly, IFN-γ KO mice cannot reject the TNF-α-secreting tumors, but highly effective anti-IFN-γ mAbs cannot restore tumor growth.
31. + T lymphocytes into effector CTL J Immunol 172 2004 6558 6567
32. + T cells J Exp Med 198 2003 569 580
33. + T cells fail to reject established tumors, except in the case of tumor-bearing mice which were pretreated with CpG oligonucleotides. The authors argue that the pretreatment enables efficient T cell infiltration.
34. M.T. Spiotto, P. Yu, D.A. Rowley, M.I. Nishimura, S.C. Meredith, T.F. Gajewski, Y.X. Fu, and H. Schreiber Increasing tumor antigen expression overcomes "Ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells Immunity 17 2002 737 747
35. T. Nishimura, K. Iwakabe, M. Sekimoto, Y. Ohmi, T. Yahata, M. Nakui, T. Sato, S. Habu, H. Tashiro, M. Sato, and A. Ohta Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo J Exp Med 190 1999 617 627
36. M.J. Dobrzanski, J.B. Reome, and R.W. Dutton Type 1 and type 2 CD8+ effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor J Immunol 164 2000 916 925
37. M.J. Dobrzanski, J.B. Reome, and R.W. Dutton Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection J Immunol 167 2001 424 434
38. J. Mattes, M. Hulett, W. Xie, S. Hogan, M.E. Rothenberg, P. Foster, and C. Parish Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process J Exp Med 197 2003 387 393
39. R.I. Tepper, P.K. Pattengale, and P. Leder Murine interleukin-4 displays potent anti-tumor activity in vivo Cell 57 1989 503 512
40. H. Hock, M. Dorsch, U. Kunzendorf, Z. Qin, T. Diamantstein, and T. Blankenstein Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma Proc Natl Acad Sci USA 90 1993 2774 2778
41. G.D. Sempowski, M.P. Beckmann, S. Derdak, and R.P. Phipps Subsets of murine lung fibroblasts express membrane-bound and soluble IL-4 receptors. Role of IL-4 in enhancing fibroblast proliferation and collagen synthesis J Immunol 152 1994 3606 3614
42. T. Kodera, T.L. McGaha, R. Phelps, W.E. Paul, and C.A. Bona Disrupting the IL-4 gene rescues mice homozygous for the tight-skin mutation from embryonic death and diminishes TGF-beta production by fibroblasts Proc Natl Acad Sci USA 99 2002 3800 3805
43. J.L. Camps, S.M. Chang, T.C. Hsu, M.R. Freeman, S.J. Hong, H.E. Zhau, A.C. von Eschenbach, and L.W. Chung Fibroblast-mediated acceleration of human epithelial tumor growth in vivo Proc Natl Acad Sci USA 87 1990 75 79
44. A. Noel, M.C. De Pauw-Gillet, G. Purnell, B. Nusgens, C.M. Lapiere, and J.M. Foidart Enhancement of tumorigenicity of human breast adenocarcinoma cells in nude mice by matrigel and fibroblasts Br J Cancer 68 1993 909 915
45. A.F. Olumi, G.D. Grossfeld, S.W. Hayward, P.R. Carroll, T.D. Tlsty, and G.R. Cunha Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium Cancer Res 59 1999 5002 5011
46. T. Schüler, S. Körnig, and Th. Blankenstein Tumor rejection by modulation of tumor stroma fibroblasts J Exp Med 198 2003 1487 1493 IL-4 secreting tumors are rejected by modulation of tumor-associated fibroblasts. It is suggested that in the presence of IL-4 the fibroblasts differentiate to a phenotype that is not able to participate in tumor-induced angiogenesis.
47. M. Saleh, I.D. Davis, and A.F. Wilks The paracrine role of tumour-derived mIL-4 on tumour-associated endothelium Int J Cancer 72 1997 664 672
48. O.V. Volpert, T. Fong, A.E. Koch, J.D. Peterson, C. Waltenbaugh, R.I. Tepper, and N.P. Bouck Inhibition of angiogenesis by interleukin 4 J Exp Med 188 1998 1039 1046
49. G. Richter, S. Krüger-Krasagakes, G. Hein, C. Hüls, E. Schmitt, T. Diamantstein, and Th. Blankenstein Interleukin 10 gene transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration Cancer Res 53 1993 4134 4137
50. P.J. Polverini, and J. Leibovich Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages Lab Invest 51 1984 635 642
51. E.Y. Lin, A.V. Nguyen, R.G. Russell, and J.W. Pollard Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy J Exp Med 193 2001 727 740
52. E. Di Carlo, A. Coletti, A. Modesti, M. Giovarelli, G. Forni, and P. Musiani Local release of interleukin-10 by transfected mouse adeno-carcinoma cells exhibits pro- and anti-inflammatory activity and results in a delayed tumor rejection Eur Cytokine Netw 9 1998 61 68
53. S. Huang, K. Xie, C.D. Bucana, S.E. Ullrich, and M. Bar-Eli Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells by inhibition of angiogenesis Clin Cancer Res 2 1996 1969 1979
54. Th. Blankenstein Observations with tumour necrosis factor gene-transfected tumours Folia Biol 40 1994 19 28
55. R.D. Schreiber, L.J. Old, A.C. Hayday, and M.J. Smyth Reply to: A cancer immunosurveillance controversy Nat Immunol 5 2004 4 5
56. •].
57. •], the authors discuss the fact that current tumor models do not support the conclusion that immune surveillance, the spontaneous recognition and elimination of primary tumors by T cells, exists against tumors without viral association.